Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis

European Respiratory Journal

Volumn 40, Issue 6, 2012, Pages 1430-1442

  Sotgiu, Giovanni ^a   Centis, Rosella ^b   D'Ambrosio, Lia ^b   Alffenaar, Jan William C ^c   Anger, Holly A ^d   Caminero, Jose A ^e,f   Castiglia, Paolo ^a   De Lorenzo, Saverio ^g   Ferrara, Giovanni ^h,i   Koh, Won Jung ^j   Schecter, Giesela F ^k   Shim, Tae S ^l   Singla, Rupak ^m   Skrahina, Alena ⁿ   Spanevello, Antonio ^b,o   Udwadia, Zarir F ^p   Villar, Miquel ^q   Zampogna, Elisabetta ^b   Zellweger, Jean Pierre ^r   Zumla, Alimuddin ^s   Migliori, Giovanni Battista ^b   more..

^a UNIVERSITY OF SASSARI   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^f INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^g Reference Hospital for MDR and HIV TB   (Italy)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j Sungkyunkwan University School of Medicine   (South Korea)

^k Division of Communicable Disease Control   (United States)

^l University of Ulsan College of Medicine   (South Korea)

^m Lala Ram Sarup Institute of Tuberculosis and Respiratory Diseases   (India)

ⁿ National Research and Practical Centre for Pulmonology and Tuberculosis   (Belarus)

^o UNIVERSITY OF INSUBRIA   (Italy)

^p P D HINDUJA NATIONAL HOSPITAL   (India)

^q Lung Diseases Centre of Venda Nova   (Portugal)

^r UNIVERSITY OF LAUSANNE   (Switzerland)

^s UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Efficacy; Extensively drug resistant tuberculosis; Linezolid; Multidrug resistant tuberculosis; Safety; Tolerability

Indexed keywords

LINEZOLID; TUBERCULOSTATIC AGENT;

ANEMIA; ARTICLE; BLOOD TOXICITY; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; SPUTUM CULTURE; SPUTUM SMEAR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PATIENT SAFETY; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84864518733     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00022912     Document Type: Article

References (47)

1. World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Publication No.WHO/HTM/TB/2010.3. Geneva, World Health Organization, 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191-eng.pdf
2. World Health Organization. Global Tuberculosis Control 2011: WHO Report 207. Publication No. WHO/HTM/TB/2011.16. Geneva, World Health Organization, 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241564380- eng.pdf
3. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430-432.
4. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
5. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-905.
6. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
7. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
8. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
9. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
10. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
11. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
12. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and longterm survival in patients with extensively drug resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-1082.
13. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
14. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
15. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J 2011; 37: 441-462.
16. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53: 1314-1319.
17. Tato M, de la Pedrosa EG, Cantón R, et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006; 28: 75-78.
18. Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005; 26: 78-80. (Pubitemid 40854121)
19. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47: 416-417. (Pubitemid 36070399)
20. Rodríguez JC, RuizM, LópezM, et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-467. (Pubitemid 35379989)
21. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-1982. (Pubitemid 34072884)
22. Fortún J, Martín-Dávila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
23. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008; 178: 1180-1185.
24. Nannini EC, Keating M, Binstock P, et al. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect 2002; 44: 201-203. (Pubitemid 36104778)
25. Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, et al. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001; 33: 1433-1434. (Pubitemid 32955202)
26. Morales P, Ros JA, Blanes M, et al. Successful recovery after disseminated infection due to Mycobacterium abscessus in a lung transplant patient: subcutaneous nodule as first manifestation - a case report. Transplant Proc 2007; 39: 2413-2415. (Pubitemid 47418204)
27. Hoetzenecker W, Ulmer A, Klingel K, et al. Dissemination of a localized cutaneous infection with Mycobacterium chelonae under immunosuppressive treatment. Arch Dermatol 2007; 143: 951-952. (Pubitemid 47076507)
28. Kyle SD, Porter WM. Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid. Br J Dermatol 2004; 151: 1101. (Pubitemid 39573905)
29. Ntziora F, Falagas ME. Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review. Int J Tuberc Lung Dis 2007; 11: 606-611. (Pubitemid 46868619)
30. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
31. Singla R, Caminero JA, Jaiswal A, et al. Linezolid, an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
32. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. Eur Respir J 2010; 35: 936-938.
33. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730-733.
34. Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-783.
35. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 770-772.
36. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375: 1814-1829.
37. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
38. Yew WW, Chau CH, Wen KH. Linezolid in the treatment of "difficult" multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 345-346. (Pubitemid 351361909)
39. Yew WW, Chang KC, Chau CH. What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Eur Respir J 2009; 34: 1492-1494.
40. Sotgiu G, Lange C, Richardson MD, et al. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 879-883.
41. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
42. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
43. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
44. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006; 52: 92-96. (Pubitemid 43137390)
45. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-704. (Pubitemid 44288145)
46. Nam HS, Koh WJ, Kwon OJ, et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009; 33: 92-93.
47. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.